Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients

NCT ID: NCT05691361

Last Updated: 2026-01-22

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 53 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-12-14
• Study Completion Date: 2027-12-30

Brief Summary

The first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-324 in healthy volunteers (HV) and in patients with Hereditary Angioedema (HAE).

Detailed Description

The clinical study described in this protocol is a Phase 1, single-center study evaluating safety, tolerability, PK, and PD of ADX-324.

The study consists of 2 parts:

• Randomized, double-blind, placebo-controlled, parallel group, single ascending dose (SAD) in HV with up to 6 dose cohorts. For SAD cohorts and planned dosing; and,
• Expansion cohort in participants with Hereditary Angioedema (HAE) at selected dose from Part A and will be open label.

Conditions

Hereditary Angioedema

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

PART A - Active ADX-324 administered to HV

For each cohort in Part A (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-324): 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.

Group Type: EXPERIMENTAL

ADX-324

Intervention Type: DRUG

siRNA duplex oligonucleotide

PART A- Placebo administered to HV

For each cohort in Part A (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-324): 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

saline

PART B - ADX-324 administered to HAE participants

This will be initiated at the dose level determined by the Safety Review Committee from SAD in HVs. The treatment of HAE participants is an open-label study.

Group Type: EXPERIMENTAL

ADX-324

Intervention Type: DRUG

siRNA duplex oligonucleotide

Interventions

ADX-324

siRNA duplex oligonucleotide

Intervention Type: DRUG

Placebo

saline

Intervention Type: DRUG

Other Intervention Names

siRNA; Saline

Eligibility Criteria

Inclusion Criteria

1. Male and female adults 18 to 55 years old

2. Body mass index (BMI) between 18 and 30 kg/m2

3. Contraception use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies

4. Willing and able to provide informed consent and comply with all study visits

1. Male and female ≥18 years old, inclusive, at the time of signing the PICF

2. Confirmed diagnosis of HAE Types I or II

3. Evidence of an average of (at least) one HAE attack per month

4. Participants must have access to, and the ability to use, acute medication(s) to treat angioedema attacks.

5. Body mass index (BMI) between 18 and 30 kg/m2

6. Contraception use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies

7. Willing and able to provide informed consent and comply with all study visits

Exclusion Criteria

1. Any significant medical history

2. Active malignancy and/or history of malignancy in the past 5 years

3. History of liver disease, Gilbert's syndrome, or abnormal liver function test

4. Estimated creatinine clearance <60 mL/min or serum creatinine > 1.5-fold upper limit of normal.

5. Any active infection or acute illness

6. Major surgery or significant traumatic injury occurring within 3 months

7. Have any other conditions that, in the opinion of the Investigator or Sponsor, would make the participant unsuitable for inclusion, or could interfere with the participant participating in or completing the study.

8. Positive serology tests (HepB, Hep C, HIV)

9. Use of any prescription, vaccines, supplements/vitamins, or over-the counter medication

10. Treatment with another investigational product within 30 days prior to the first study drug administration

11. Known any clinically significant allergic reactions which, in the opinion of the Investigator, would interfere with the volunteer's ability to participate in the study

12. Known hypersensitivity to any of the study drug ingredients.

13. Pregnancy, intent to become pregnant during the course of the study, or lactating women

Part B - HAE

1. Concurrent diagnosis of any other type of chronic angioedema

2. History of clinically significant arterial or venous thrombosis, or current history of a clinically significant prothrombotic risk.

3. Any significant medical history

4. Active malignancy and/or history of malignancy in the past 5 years

5. Any active infection or acute illness, inclusive of cold/flu or COVID-19, within 30 days prior to the first study drug administration.

6. Major surgery or significant traumatic injury occurring within 3 months prior to signature of the PICF

7. Have any other conditions that, in the opinion of the Investigator or Sponsor, would make the participant unsuitable for inclusion, or could interfere with the participant participating in or completing the study.

8. Positive serology tests for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).

9. Use of C1-INH products, androgens, antifibrinolytics or other small molecule medications for routine prophylaxis within four half-lives prior to screening

10. Must have documented evidence of medical history of HAE attacks

11. Use of any prescription, vaccines, supplements/vitamins, or over-the counter medication (with the exception of oral contraceptives) within 7 days prior to the first study drug administration.

12. Treatment with another investigational product or biologic agent within 30 days prior to the study drug administration

13. History or presence of alcohol abuse or drug use within 30 days prior to the first study drug administration and throughout the study.

14. Blood donation of 50 to 499 mL within 30 days prior to the first study drug administration or of >499 mL within 60 days prior to the first study drug administration.

15. Pregnancy, intent to become pregnant during the course of the study, or lactating women.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Avance Clinical Pty Ltd.

INDUSTRY

Sponsor Role: collaborator

ADARx Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Masako Marai, MD

Role: STUDY_DIRECTOR

ADARx Pharmaceuticals

Locations

CMAX Clinical Research

Adelaide, South Australia, Australia

Countries

Australia

Other Identifiers

ADX-324-101

Identifier Type: -

Identifier Source: org_study_id